Please use this identifier to cite or link to this item: http://hdl.handle.net/1942/14308
Title: Systemic anti-vascular endothelial growth factor therapies induce a painful sensory neuropathy
Authors: Verheyen, An
PEERAER, Eve 
Nuydens, Rony
Dhondt, Joke
Poesen, Koen
Pintelon, Isabel
Daniels, Anneleen
Timmermans, Jean-Pierre
MEERT, Theo 
Carmeliet, Peter
Lambrechts, Diether
Issue Date: 2012
Publisher: OXFORD UNIV PRESS
Source: BRAIN, 135, p. 2629-2641
Abstract: Systemic vascular endothelial growth factor inhibition, in combination with chemotherapy, improves the outcome of patients with metastatic cancer. Peripheral sensory neuropathies occurring in patients receiving both drugs are attributed to the chemotherapy. Here, we provide unprecedented evidence that vascular endothelial growth factor receptor inhibitors trigger a painful neuropathy and aggravate paclitaxel-induced neuropathies in mice. By using transgenic mice with altered neuronal vascular endothelial growth factor receptor expression, systemic inhibition of vascular endothelial growth factor receptors was shown to interfere with the endogenous neuroprotective activities of vascular endothelial growth factor on sensory neurons. In vitro, vascular endothelial growth factor prevented primary dorsal root ganglion cultures from paclitaxel-induced neuronal stress and cell death by counteracting mitochondrial membrane potential decreases and normalizing hyperacetylation of a-tubulin. In contrast, vascular endothelial growth factor receptor inhibitors exerted opposite effects. Intriguingly, vascular endothelial growth factor or vascular endothelial growth factor receptor inhibitors exerted their effects through a mechanism whereby Hdac6, through Hsp90, controls vascular endothelial growth factor receptor-2-mediated expression of the anti-apoptotic Bcl2. Our observations that systemic anti-vascular endothelial growth factor therapies interfere with the neuroprotective activities of vascular endothelial growth factor may have important implications for the application of anti-vascular endothelial growth factor therapies in cancer patients.
Notes: [Verheyen, An; Dhondt, Joke; Poesen, Koen; Lambrechts, Diether] Univ Louvain, Dept Oncol, Lab Translat Genet, B-3000 Louvain, Belgium. [Verheyen, An; Dhondt, Joke; Poesen, Koen; Carmeliet, Peter; Lambrechts, Diether] VIB, Vesalius Res Ctr, B-3000 Louvain, Belgium. [Verheyen, An; Peeraer, Eve; Nuydens, Rony; Daniels, Anneleen; Meert, Theo] Janssen Res & Dev, Dept Neurosci, B-2340 Beerse, Belgium. [Peeraer, Eve] Univ Hasselt, Biomed Res Inst, B-3590 Diepenbeek, Belgium. [Pintelon, Isabel; Timmermans, Jean-Pierre] Univ Antwerp, Lab Cell Biol & Histol, Dept Vet Sci, B-2020 Antwerp, Belgium. [Carmeliet, Peter] Univ Louvain, Lab Angiogenesis & Neurovasc Link, B-3000 Louvain, Belgium. diether.lambrechts@vib-kuleuven.be
Keywords: anti-angiogenesis; histone deacetylase 6; neuropathy; vascular endothelial growth factor;Clinical Neurology; Neurosciences; anti-angiogenesis; histone deacetylase 6; neuropathy; vascular endothelial growth factor
Document URI: http://hdl.handle.net/1942/14308
ISSN: 0006-8950
e-ISSN: 1460-2156
DOI: 10.1093/brain/aws145
ISI #: 000308873600007
Category: A1
Type: Journal Contribution
Validations: ecoom 2013
Appears in Collections:Research publications

Show full item record

SCOPUSTM   
Citations

28
checked on Sep 3, 2020

WEB OF SCIENCETM
Citations

39
checked on May 14, 2022

Page view(s)

68
checked on May 20, 2022

Google ScholarTM

Check

Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.